Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors
- 50 Downloads
Vactosertib, a novel inhibitor of transforming growth factor-β type Ι receptor, is under development for the treatment of various cancers. The objective of this study was to characterize the population pharmacokinetics of vactosertib in patients with solid tumors.
Vactosertib population pharmacokinetics was assessed by nonlinear mixed-effects modelling of plasma concentration–time data obtained from a first-in-human phase 1 trial conducted in patients with advanced solid tumors. The final population pharmacokinetic model was constructed by assessing the effect of covariates on pharmacokinetic parameters including demographic characteristics, laboratory values, hepatic and renal function, and concomitant medications. The robustness of the final model was evaluated using a bootstrap method as well as visual predictive check based on Monte Carlo simulations and goodness-of-fit plots.
A total of 559 concentrations from 29 patients were available for pharmacokinetic analysis. A two-compartment linear model with first-order absorption and absorption lag time adequately described the population pharmacokinetics of vactosertib. The estimates of apparent clearance (CL/F) and volume of central compartment (Vc/F) were 31.9 L/h (inter-individual variability, 0.481) and 82.9 L (inter-individual variability, 0.534), respectively. The mixture model accounts for both typical absorption profile in the majority of patients and distinct profile in some patients with uncommon gastrointestinal conditions. Body mass index was significantly associated with Vc/F.
The model developed in this study adequately describes the population pharmacokinetics of vactosertib in patients with advanced solid tumors. The pharmacokinetic characteristics assessed using the model would provide useful quantitative information to assist the future clinical development of vactosertib.
KeywordsVactosertib TGF-β signaling inhibitor Population pharmacokinetics Phase 1 Solid tumors
The authors would like to acknowledge all the patients and study personnel who participated in the phase 1 study. This work was supported by the Research Institutes of Pharmaceutical Science in Seoul National University. Additional support was provided by the National OncoVenture/National Cancer Center funded by Ministry of Health and Welfare, Republic of Korea (No. HI17C2196).
This study was sponsored by MedPacto, Inc.
Compliance with ethical standards
Conflict of interest
JIL and EKC have received research funding from MedPacto, Inc. JMC, TMB and VLK received grant from MedPacto, Inc. for conduct of the phase 1 clinical trial as principal investigators. JMC has received research grant as a principal investigator from Bristol-Myers Squibb, Eli Lilly, Genentech, Spectrum, Adaptimmune, MedPacto, Bayer, AbbVie, and Moderna, and served as an advisory consultant for AstraZeneca, Guardant, Merck and Eli Lilly. TMB has received research grant from Daiichi Sankyo, Incyte, Mirati Therapeutics, MedImmune, Abbvie, AstraZeneca, Merck, Eli Lilly, GlaxoSmithKline, Novartis, Genentech, Deciphera, Merrimack, Immunogen, Millennium, Roche, Aileron Therapeutics, Bristol-Myers Squibb, Amgen, Onyx, Sanofi, Boehringer-Ingelheim, Astellas Pharma, Janssen, Clovis Oncology, Takeda, Karyopharm Therapeutics, Foundation Medicine, and ARMO Biosciences. VLK is a consultant for Karyopharm Therapeutics, and has research funding from Plexxicon, Eli Lilly, Daiichi Sankyo, BioMed Valley Discoveries, Immune Design, GlaxoSmithKline, TRACON Pharma, and Advenchen Laboratories. SJK has a personal financial interest as a shareholder in MedPacto, Inc. SH is an employee of MedPacto, Inc. Other remaining authors have nothing to disclose.
All procedures involving human participants performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Rao KS, Lee HJ, Park S-J, Park H-J, Lee K, Sheen YY, Kim D-K (2014) Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent. J Med Chem 57(10):4213–4238. https://doi.org/10.1021/jm500115w CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Kim MJ, Park SA, Kim CH, Park SY, Kim JS, Kim DK, Nam JS, Sheen YY (2016) TGF-beta type I receptor kinase inhibitor EW-7197 suppresses cholestatic liver fibrosis by inhibiting HIF1alpha-induced epithelial mesenchymal transition. Cell Physiol Biochem 38(2):571–588. https://doi.org/10.1159/000438651 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Yoon JH, Jung SM, Park SH, Kato M, Yamashita T, Lee IK, Sudo K, Nakae S, Han JS, Kim OH, Oh BC, Sumida T, Kuroda M, Ju JH, Jung KC, Park SH, Kim DK, Mamura M (2013) Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes. EMBO Mol Med 5(11):1720–1739. https://doi.org/10.1002/emmm.201302524 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Keedy VL, Bauer TM, Clarke JM, Hurwitz H, Baek I, Ha I, Ock C-Y, Nam SY, Kim M, Park N, Kim JY, Kim S-J (2018) Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors. Journal of Clinical Oncology 36(15_suppl):3031. https://doi.org/10.1200/jco.2018.36.15_suppl.3031 CrossRefGoogle Scholar
- 10.Food, Administration D (2003) Exposure-response relationships–study design, data analysis, and regulatory applications. Guidance for IndustryGoogle Scholar
- 15.Williams PJ, Ette EI (2000) The role of population pharmacokinetics in drug development in light of the food and drug administration’s ‘guidance for industry: population pharmacokinetics’. Clin Pharmacokinet 39(6):385–395. https://doi.org/10.2165/00003088-200039060-00001 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Yu M, Gao Z, Dai X, Gong H, Zhang L, Chen X, Zhong DF, Sy SK (2017) Population pharmacokinetic and covariate analysis of apatinib, an oral tyrosine kinase inhibitor, in healthy volunteers and patients with solid tumors. Clin Pharmacokinet 56(1):65–76. https://doi.org/10.1007/s40262-016-0427-y CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Lacy S, Yang B, Nielsen J, Miles D, Nguyen L, Hutmacher M (2018) A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types. Cancer Chemother Pharmacol 81(6):1071–1082. https://doi.org/10.1007/s00280-018-3581-0 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Robarge JD, Metzger IF, Lu J, Thong N, Skaar TC, Desta Z, Bies RR (2017) Population pharmacokinetic modeling to estimate the contributions of genetic and nongenetic factors to efavirenz disposition. Antimicrob Agents Chemother 61(1):e01813–e01816. https://doi.org/10.1128/aac.01813-16 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Klünder B, Mittapalli RK, Mohamed M-EF, Friedel A, Noertersheuser P, Othman AA (2019) Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials. Clin Pharmacokinet. https://doi.org/10.1007/s40262-019-00739-3 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Mudie DM, Murray K, Hoad CL, Pritchard SE, Garnett MC, Amidon GL, Gowland PA, Spiller RC, Amidon GE, Marciani L (2014) Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state. Mol Pharm 11(9):3039–3047. https://doi.org/10.1021/mp500210c CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Steingoetter A, Fox M, Treier R, Weishaupt D, Marincek B, Boesiger P, Fried M, Schwizer W (2006) Effects of posture on the physiology of gastric emptying: a magnetic resonance imaging study. Scand J Gastroenterol 41(10):1155–1164. https://doi.org/10.1080/00365520600610451 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Jung SY, Hwang S, Clarke JM, Bauer TM, Keedy VL, Lee H, Park N, Kim SJ, Lee JI (2019) Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. Invest New Drugs. https://doi.org/10.1007/s10637-019-00835-y CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Traverso LW (2007) Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the international study group of pancreatic surgery (ISGPS). Surgery 142(5):761–768CrossRefGoogle Scholar
- 41.McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NHG (2014) Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and bayesian dose personalization. J Clin Cancer Res 20(3):754–763. https://doi.org/10.1158/1078-0432.CCR-13-1960 CrossRefGoogle Scholar
- 50.Baathe S, Hamren B, Karlsson MO, Wollbratt M, Grind M, Eriksson UG (2006) Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy. Clin Pharmacokinet 45(8):803–819. https://doi.org/10.2165/00003088-200645080-00004 CrossRefPubMedPubMedCentralGoogle Scholar